<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455442</url>
  </required_header>
  <id_info>
    <org_study_id>C-1073-200</org_study_id>
    <nct_id>NCT00455442</nct_id>
  </id_info>
  <brief_title>A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain</brief_title>
  <official_title>A Two-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-week study testing the efficacy and safety of mifepristone in the prevention of
      olanzapine-induced weight gain in healthy male volunteers by measuring changes in body weight
      and BMI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the tolerability and safety of the administration of mifepristone and olanzapine in healthy male volunteers.</measure>
  </secondary_outcome>
  <enrollment type="Actual">57</enrollment>
  <condition>Weight-Gain Prevention</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers between 18 and 40 years of age

          -  BMI between ≥ 18 and ≤ 25

          -  Able to provide written informed consent

          -  Routine clinical laboratory tests either within normal limits or not clinically
             meaningful if outside of normal limits

        Exclusion Criteria:

          -  History of Cushing's syndrome or Addison's disease

          -  Prior or current history of any psychiatric disorder, including eating disorders such
             as anorexia nervosa, bulimia nervosa, or binge-eating disorder

          -  Positive urine drug screen for any non-prescribed drug of abuse (including but not
             limited to amphetamines, cannabinoids, barbiturates, cocaine, opiates,
             benzodiazepines)

          -  Participation in a clinical investigation of any drug, biological or other
             investigational therapy within 30 days prior to dosing

          -  Have a history of an allergic reaction to either mifepristone or olanzapine

          -  Any clinically significant abnormality on screening laboratory tests

          -  QTc Bazzett's ≥ 450 msec

          -  Any major medical condition, which in the opinion of the Investigator would place the
             patient at undue risk.

          -  Receiving any prescription or over-the-counter medications that could potentially
             affect appetite or weight

          -  History of recent (within 6 months of screening) significant weight fluctuation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thad Block, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. John's Medical College</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.corcept.com</url>
    <description>Corcept Therapeutics official website</description>
  </link>
  <reference>
    <citation>Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.</citation>
    <PMID>16782211</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

